# Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

> **NCT00061815** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 102 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** oxaliplatin
- **DRUG:** leucovorin
- **DRUG:** 5-fluorouracil
- **DRUG:** 5-fluorouracil
- **BIOLOGICAL:** cetuximab

## Key facts

- **NCT ID:** NCT00061815
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2004-12
- **Final completion:** 2005-11
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2010-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061815, "Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00061815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*